Latest Breaking News On - Seelo annual report - Page 1 : comparemela.com

Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which includes the exercise in full by the underwriters of their option to … – Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to Seelos from this offering are expected to be approximately $64

New yorkUnited statesAnthony marcianoExchange commissionEquity syndicate departmentSeelos therapeutics incHead of corporate communicationsGuggenheim securitiesSeelos therapeuticsBenchmark companyAcute suicidal ideationMajor depressive disorderPost traumatic stress disorderLooking statementsPrivate securities litigation reform actSeelo annual report